Shionogi Signs Development & Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD & ASD

 Shionogi Signs Development & Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD & ASD

Shionogi Signs Development & Commercialization Agreement with Akili for its AKL-T01 and AKL-T02 for ADHD & ASD

Shots:

  • Akili to receive $20M upfront, $105M as development & commercialization milestones, making the total the deal value $125M & royalties on sales of the products. Shionogi to get exclusive development & commercialization rights for Akili’s digital medicine, AKL-T01 and AKL-T02 in Japan and Taiwan
  • Acc. to an agreement, Shionogi will be responsible for regulatory filings in Japan & Taiwan. Akili has an exclusive global right to develop & commercialize its digital medicines excluding Japan & Taiwan
  • Akili’s AKL-T01 and AKL-T02 are a digital treatment for attention-deficit/hyperactivity disorder (ADHD) & Autism Spectrum Disorder (ASD) respectively in children

Click here to read full press release/ article | Ref: Akili | Image: Business Wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post